Subscribe
Search
Close this search box.
Subscribe
Search
Close this search box.

Discovery and research, Industrial application

Belgium leads the way in advancing ATMPs

ATMPs (advanced therapy medicinal products) are expected to reach a global value of 80 billion euro in 2032. While it can be tempting to try to go it alone, the fastest and most intelligent way to advance is by advancing together. The event, Advanced Therapies in Belgium, presents such an occasion, offering a space for innovative ideas and featuring speakers from the forefront of the Belgian and international ATMP innovation.

The rise and recalibration of sustainable agrifood investments: lessons for us all

There has been an unprecedented surge of investments in sustainable agriculture and food technologies in the last decade, but that trend now appears to have reversed into a free fall in funding. This pattern of promise-to-disillusionment perfectly matches the hype cycle previously demonstrated by breakthrough technologies in other sectors. Can we forge a path forward for sustainable agrifood start-ups?

Belgium’s ‘Positive for the Planet’ evolution through agritech

Our current food system is responsible for around a third of global greenhouse gas emissions, extensive deforestation, unsustainable water usage, and an unprecedented loss of biodiversity. Currently, the processes used to produce our food represent an obstacle to limiting average global temperature increases to the levels set out in the Paris Agreement. But are these damaging effects of our current food production landscape an unavoidable cost of feeding humanity or can smart investments in sustainable agritech be part of the solution?

Incorporating sustainability into healthcare

In a hospital, numerous single-use masks, gloves, syringes, and more are thrown away every day to safeguard patients. However, this linear supply chain leaves a large footprint and can have negative effects on our environment and public health. It seems that the road to achieving sustainable healthcare is not straightforward, but circular.

Bridging the gap between academia and the sports tech industry

For scientists or budding entrepreneurs with the next big idea in sports tech, the road from conceptualization to product can seem perilous, with many pitfalls along the way. To stand a chance at getting your research out of the lab and into the hands of athletes, it’s essential to start off on the right foot. Read on to see how the collaboration of scientists and sports tech development experts is helping this unique ecosystem in Belgium to flourish.

Monitoring muscles in motion with wearable ultrasound technology

Ultrasound is a powerful technology that helps healthcare professionals take the first images of your child in utero and allows us to look at soft tissue, such as muscles, tendons, and most internal organs. But ultrasound largely requires patients to be static, meaning crucial information is missed about how muscles or organs behave when they’re most strained during exercise. Now, novel advances and innovative designs from the Netherlands and beyond are bringing ultrasound devices into the wearable medtech era, with exciting possibilities to monitor muscles and organs in motion. These technologies are pushing boundaries in both the medical and sports worlds while helping to diagnose patients, to help athletes train, or to shorten their road to recovery.

Athlete versus pain, an inevitable battle?

Training session after training session, top athletes must push themselves to the limits to test their bodies. Although pain is a clear emergency signal, athletes in pain may push themselves even further. This makes them vulnerable to injuries and severe pain conditions including acute and chronic lower back pain. Although there are several treatment options to alleviate the symptoms, the treatment of acute and chronic pain is not straightforward. A multidisciplinary approach is required, and more treatment options are needed that focus on treating the underlying cause.

Flanders as a knowledge hub in the current Benelux life sciences ecosystem

At the heart of Europe, Benelux is like a drop of ink spreading its influence internationally; an in-depth study conducted by KBC Securities placed Belgium as Europe’s leading country for biotech in 2024. This year's edition of Knowledge for Growth, hosted by the life sciences cluster flanders.bio celebrating their 20th anniversary, highlighted the vibrant Flemish life sciences ecosystem. The event took place in Antwerp, Belgium on May 15th and 16th, where industry professionals, scientists, investors, policymakers, and more gathered to share their knowledge and insights and answer why the region of Flanders, and the Benelux overall, are doing so well in this vibrant landscape.

Retaining female talents

While the life sciences environment is adjusting to be able to foster female talents in the workplace, there is still a long way to go to achieve truly egalitarian work conditions. From the ‘motherhood penalty’ to unconscious bias, women can still be made to feel unwelcome in their daily work life. This is what motivated Veroniek Vermeulen to launch Silatha, a company with the goal of creating an environment where everyone can thrive.

The women of BioVox

STEM has had a long reputation of being a masculine environment, though recent efforts have made this field much more accessible to all genders. Our gender can influence both the external factors and internal methods affecting how we work.

Fraud in scientific institutes: a crack in the fabric of science

The pursuit of scientific knowledge is at the heart of human progress – it leads to ground-breaking discoveries that have transformed our understanding of the world and our place within it. However, this noble pursuit is not without its blemishes. Scientific fraud – the deliberate misrepresentation of data or results to deceive the scientific community – poses a serious threat to the integrity of the scientific enterprise in both academia and industry. So, what can we do about it?

Fund+ portfolio company Cardior Pharmaceuticals to be acquired by Novo Nordisk in potential 1-billion-euro deal

Novo Nordisk will acquire Cardior Pharmaceuticals for up to 1.025 billion euros, including upfront and additional payments if certain development and commercial milestones are achieved. Cardior is a leader in RNA-based therapies that have the potential to prevent, repair and reverse diseases of the heart. The company’s approach targets distinctive non-coding RNAs to address the root causes of cardiac dysfunctions and achieve lasting patient impact.

Fund+ Portfolio Company Tubulis Closes Upsized EUR 128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Azalea Vision Secures Prestigious European Innovation Council (EIC) Transition Grant

Innovative Smart Contact Lens Developer Awarded €2.5M in Funding for Groundbreaking Ocular Health Technology

Bridging the immunity gap: improving animal welfare without antibiotics

Antibiotic resistance is a major concern for humans and animals. Increasing pressure to move away from antibiotics has created space for new solutions for disease management. Animab’s oral monoclonal antibody platform is a promising alternative, effectively guarding against infection during a vulnerable period in an animal’s development.